Elucida Oncology
Manufacturing · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1 Deerpark Dr Ste E, Monmouth Junction, ...Phone Number
(732) 823-1182Website
www.elucidaoncology.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Elucida Oncology
Elucida Oncology, Inc., is a privately held, clinical-stage biotechnology company focused on developing and commercializing a first-in-class ultra-small nanoparticle platform for the diagnosis, visualization and treatment of primary solid tumor and metastatic cancers. The novel Target or Clear characteristic of the C-Dot product platform is demonstrating the combination of advanced cancer cell targeting combined with the potential safety advance afforded by bulk clearance through the renal system.Explore more
Elucida Oncology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Elucida Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Elucida Oncology
Funding: Get notified immidiatlly once Elucida Oncology has new funding data
Check out if Elucida Oncology is spiking on competitors!
Earning: See what the market has to say on Elucida Oncology recently announced quarterly report
Elucida Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Elucida Oncology had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Elucida Oncology launches new products
Website visits: Recent activity has been detected on your website
Check if Elucida Oncology has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Elucida Oncology as Masked Content
Find 3 more new buyers
Compare Similar Companies to Elucida Oncology
Compare insights from companies similar to Elucida Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Elucida Oncology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Elucida Oncology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Elucida Oncology.
Elucida Oncology financials insights
Gather financial insights about Elucida Oncology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$10.9M
2021
Series A
$72M
Elucida Oncology Tech Stack
A closer look at the technologies used by Elucida Oncology
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Board of Directors
Left Company
Executive Move
New Hire
Executive Move
New Hire
Executive Move
Elucida Oncology News & Media
Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an Anti-Folate Receptor Alpha C’Dot Drug Conjugate
MONMOUTH JUNCTION, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, presented positive initial safety data from Phase 1 dose escalation trial of ELU001 (NCT05001282) in a poster titled “ELU-FRα-1: A Study to Evaluate ELU001, a C’Dot Drug Conjugate, in Patients with Solid Tumors that Overexpress Folate Receptor Alpha (FRα)” (abstract #CT255) at the American Association for Cancer Research (AAElucida Oncology to Present at the Piper Sandler 34th Annual Healthcare Conference
MONMOUTH JUNCTION, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that management will participate at the Piper Sandler 34th Annual Healthcare Conference, taking place at the Lotte New York Palace on November 29-December 1, 2022. Geno Germano, President and CEO, will be presenting on behalf of the company, and will also be available for 1X1 investor meetings along with EluciElucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting
MONMOUTH JUNCTION, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today the Company will present a Trials in Progress poster presentation for the Phase 1/2 Study of ELU001 in patients with advanced, recurrent, or refractory cancers overexpressing Folate-Receptor Alpha (FRα), at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually from June 3-7, 2022Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference
MONMOUTH JUNCTION, N. J. , May 06, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida Oncology, will present at the Bank of America 2022 Healthcare Conference in Las Vegas, NV on Tuesday, May 10, at 4:40pm PST.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Elucida Oncology
Sign Up For FreeTo access detailed company insights
Elucida Oncology, Inc., is a privately held, clinical-stage biotechnology company focused on developing and commercializing a first-in-class ultra-small nanoparticle platform for the diagnosis, visualization and treatment of primary solid tumor and metastatic cancers. The novel Target or Clear characteristic of the C-Dot product platform is demonst... Read More
